Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX-9FLT
- Development stage
- Unknown
- Lead developer
- MEDRx
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
MRX-9FLT is a transdermal patch formulation of fentanyl developed by MEDRx using its proprietary Ionic Liquid Transdermal System (ILTS) technology. It is designed for the treatment of chronic, cancer, and severe acute pain. A distinguishing feature of MRX-9FLT is its integrated safety mechanism aimed at preventing accidental exposure and misuse, which led to the U.S. FDA granting it Fast Track designation. The product is currently in Phase I clinical trials and aims to address safety concerns associated with conventional fentanyl patches while targeting the significant U.S. transdermal opioid market.
- Other names
- fentanyl transdermal patchMEDRx fentanyl patch
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on MRX-9FLT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX-9FLT.